logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Targeting The Il17 Pathway In Inflammatory Disorders 1st Edition Congqiu Chu Auth

  • SKU: BELL-5735898
Targeting The Il17 Pathway In Inflammatory Disorders 1st Edition Congqiu Chu Auth
$ 31.00 $ 45.00 (-31%)

5.0

60 reviews

Targeting The Il17 Pathway In Inflammatory Disorders 1st Edition Congqiu Chu Auth instant download after payment.

Publisher: ADIS
File Extension: PDF
File size: 1.46 MB
Pages: 112
Author: Cong-Qiu Chu (auth.)
ISBN: 9783319280394, 9783319280400, 3319280392, 3319280406
Language: English
Year: 2017
Edition: 1

Product desciption

Targeting The Il17 Pathway In Inflammatory Disorders 1st Edition Congqiu Chu Auth by Cong-qiu Chu (auth.) 9783319280394, 9783319280400, 3319280392, 3319280406 instant download after payment.

This book provides an overview of the discovery and structure of IL-17, including its pathogenesis and role in chronic inflammation and autoimmunity. To capture the latest developments and product approvals the book also discusses the therapeutic advances and looks at emerging therapies targeting the IL-17 pathway. IL-17 is a pro-inflammatory cytokine that has a key role in inflammation, autoimmunity, and host defense in a number of inflammatory disorders such as rheumatoid arthritis, psoriatic arthritis and psoriasis, ankylosing spondylitis, multiple sclerosis, and inflammatory bowel disease. The discovery of the IL-17-Th17 pathway has seen exciting development in the field of immunology and inflammation research, which has led to a number of recent regulatory approvals.

Related Products